Sprycel, also known by its generic name dasatinib, is a targeted cancer therapy. It is primarily used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) that are positive for the Philadelphia chromosome. This drug belongs to a class of medications known as tyrosine kinase inhibitors (TKIs), which work by blocking the action of an abnormal protein that signals cancer cells to multiply.
